Genentech has initiated two phase 3 trials investigating faricimab in patients with macular edema following retinal vein occlusion, according to a company announcement.
The randomized, multicenter, double-masked, active comparator-controlled, parallel-group global COMINO and BALATON trials are evaluating the efficacy and safety of faricimab in patients with macular edema secondary to central retinal vein occlusion and macular edema secondary to branch retinal vein occlusion, respectively, compared with aflibercept.
COMINO will enroll 750 patients, and BALATON will enroll 570 patients.
Both